BRIDGEWAY CAPITAL MANAGEMENT, LLC - LEAP THERAPEUTICS INC ownership

LEAP THERAPEUTICS INC's ticker is LPTX and the CUSIP is 52187K101. A total of 72 filers reported holding LEAP THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.1%.

Quarter-by-quarter ownership
BRIDGEWAY CAPITAL MANAGEMENT, LLC ownership history of LEAP THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$101,422
-24.4%
298,3010.0%0.00%0.0%
Q4 2022$134,235
-49.0%
298,3010.0%0.00%
-57.1%
Q3 2022$263,000
-23.3%
298,3010.0%0.01%
-12.5%
Q2 2022$343,000
+17.5%
298,301
+78.5%
0.01%
+33.3%
Q1 2022$292,000
-46.0%
167,1010.0%0.01%
-40.0%
Q4 2021$541,000
-45.4%
167,101
-32.4%
0.01%
-47.4%
Q3 2021$991,000
+61.7%
247,101
-33.9%
0.02%
+72.7%
Q2 2021$613,000
-26.3%
373,601
-14.7%
0.01%
-31.2%
Q1 2021$832,000
+49.6%
438,101
+77.4%
0.02%
+33.3%
Q4 2020$556,000
+30.5%
247,000
+14.9%
0.01%
+20.0%
Q3 2020$426,000
+53.2%
215,000
+61.7%
0.01%
+66.7%
Q2 2020$278,000
+561.9%
133,000
+266.4%
0.01%
+500.0%
Q3 2019$42,000
-35.4%
36,3000.0%0.00%0.0%
Q2 2019$65,000
-4.4%
36,3000.0%0.00%0.0%
Q1 2019$68,000
-6.8%
36,3000.0%0.00%0.0%
Q4 2018$73,000
-74.2%
36,3000.0%0.00%
-66.7%
Q3 2018$283,000
-13.5%
36,3000.0%0.00%0.0%
Q2 2018$327,000
+8.6%
36,3000.0%0.00%0.0%
Q1 2018$301,000
+32.6%
36,3000.0%0.00%
+50.0%
Q4 2017$227,000
+7.6%
36,3000.0%0.00%0.0%
Q3 2017$211,000
-10.6%
36,3000.0%0.00%
-33.3%
Q2 2017$236,000
-29.1%
36,3000.0%0.00%
-25.0%
Q1 2017$333,00036,3000.00%
Other shareholders
LEAP THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Perceptive Advisors 16,952,992$27,802,0000.18%
Opaleye Management Inc. 540,000$886,0000.15%
ACT CAPITAL MANAGEMENT, LLC 134,000$220,0000.11%
Artal Group S.A. 3,000,000$4,920,0000.10%
HHLR ADVISORS, LTD. 3,575,745$5,864,0000.06%
PLATINUM INVESTMENT MANAGEMENT LTD 910,047$1,492,0000.04%
PERSONAL CFO SOLUTIONS, LLC 78,165$128,0000.03%
GSA CAPITAL PARTNERS LLP 122,401$201,0000.02%
Windsor Creek Advisors, LLC 46,955$77,0000.02%
Golden Green, Inc. 14,824$24,0000.02%
View complete list of LEAP THERAPEUTICS INC shareholders